BeOne Medicines (ONC) Preferred Stock Liabilities (2015)

BeOne Medicines' (ONC) quarterly Preferred Stock Liabilities came in at $176.1 million in Q4 2015.

BeOne Medicines (ONC) Preferred Stock Liabilities (2015) Analysis & Trends

BeOne Medicines (ONC) has 1 years of Preferred Stock Liabilities data on file, last reported at $176.1 million in Q4 2015.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $176.1 million in Q4 2015; TTM through Dec 2015 was $176.1 million, a N/A change from a year earlier, with the FY2015 full-year figure at $176.1 million, changed N/A from the prior year.
Preferred Stock Liabilities for Q4 2015 stood at $176.1 million.
Over the last five years, Preferred Stock Liabilities for ONC reached as high as $176.1 million in Q4 2015 and fell as low as $176.1 million in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn	-

Download Data

Date	Value
Dec 31, 2015	176.08 Mn